These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23266047)

  • 1. Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients.
    Vincenzi B; Zoccoli A; Schiavon G; Iuliani M; Pantano F; Dell'aquila E; Ratta R; Muda AO; Perrone G; Brunelli C; Correale P; Riva E; Russo A; Loupakis F; Falcone A; Santini D; Tonini G
    Eur J Cancer; 2013 Apr; 49(6):1501-8. PubMed ID: 23266047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression levels of the microRNA processing enzymes Drosha and dicer in epithelial skin cancer.
    Sand M; Gambichler T; Skrygan M; Sand D; Scola N; Altmeyer P; Bechara FG
    Cancer Invest; 2010 Jul; 28(6):649-53. PubMed ID: 20210522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dicer, Drosha, and outcomes in patients with ovarian cancer.
    Merritt WM; Lin YG; Han LY; Kamat AA; Spannuth WA; Schmandt R; Urbauer D; Pennacchio LA; Cheng JF; Nick AM; Deavers MT; Mourad-Zeidan A; Wang H; Mueller P; Lenburg ME; Gray JW; Mok S; Birrer MJ; Lopez-Berestein G; Coleman RL; Bar-Eli M; Sood AK
    N Engl J Med; 2008 Dec; 359(25):2641-50. PubMed ID: 19092150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification.
    Díaz-García CV; Agudo-López A; Pérez C; López-Martín JA; Rodríguez-Peralto JL; de Castro J; Cortijo A; Martínez-Villanueva M; Iglesias L; García-Carbonero R; Fresno Vara JA; Gámez-Pozo A; Palacios J; Cortés-Funes H; Paz-Ares L; Agulló-Ortuño MT
    Carcinogenesis; 2013 May; 34(5):1031-8. PubMed ID: 23349018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of Dicer predicts poor survival in colorectal cancer.
    Faber C; Horst D; Hlubek F; Kirchner T
    Eur J Cancer; 2011 Jun; 47(9):1414-9. PubMed ID: 21345667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Dicer and Drosha in triple-negative breast cancer.
    Passon N; Gerometta A; Puppin C; Lavarone E; Puglisi F; Tell G; Di Loreto C; Damante G
    J Clin Pathol; 2012 Apr; 65(4):320-6. PubMed ID: 22259182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the microRNA regulators Drosha, Dicer and Ago2 in non-small cell lung carcinomas.
    Prodromaki E; Korpetinou A; Giannopoulou E; Vlotinou E; Chatziathanasiadou Μ; Papachristou NI; Scopa CD; Papadaki H; Kalofonos HP; Papachristou DJ
    Cell Oncol (Dordr); 2015 Aug; 38(4):307-17. PubMed ID: 26227789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A low Dicer expression is associated with resistance to 5-FU-based chemoradiotherapy and a shorter overall survival in patients with oral squamous cell carcinoma.
    Kawahara K; Nakayama H; Nagata M; Yoshida R; Hirosue A; Tanaka T; Nakagawa Y; Matsuoka Y; Kojima T; Takamune Y; Yoshitake Y; Hiraki A; Shinohara M
    J Oral Pathol Med; 2014 May; 43(5):350-6. PubMed ID: 24325353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The microRNA-processing enzymes: Drosha and Dicer can predict prognosis of nasopharyngeal carcinoma.
    Guo X; Liao Q; Chen P; Li X; Xiong W; Ma J; Li X; Luo Z; Tang H; Deng M; Zheng Y; Wang R; Zhang W; Li G
    J Cancer Res Clin Oncol; 2012 Jan; 138(1):49-56. PubMed ID: 21953080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deregulation of dicer and mir-155 expression in liposarcoma.
    Vincenzi B; Iuliani M; Zoccoli A; Pantano F; Fioramonti M; De Lisi D; Frezza AM; Rabitti C; Perrone G; Onetti Muda A; Russo A; Giordano A; Santini D; Dei Tos AP; Tonini G
    Oncotarget; 2015 Apr; 6(12):10586-91. PubMed ID: 25888631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inducing cell proliferation inhibition and apoptosis via silencing Dicer, Drosha, and Exportin 5 in urothelial carcinoma of the bladder.
    Han Y; Liu Y; Gui Y; Cai Z
    J Surg Oncol; 2013 Feb; 107(2):201-5. PubMed ID: 22766726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
    Pentheroudakis G; Kotoula V; Kouvatseas G; Charalambous E; Dionysopoulos D; Zagouri F; Koutras A; Papazisis K; Pectasides D; Samantas E; Dimopoulos MA; Papandreou CN; Fountzilas G
    Clin Breast Cancer; 2014 Oct; 14(5):330-8. PubMed ID: 24703319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic evaluation of the miRNA-ome and its downstream effects on mRNA expression identifies gastric cancer progression.
    Tchernitsa O; Kasajima A; Schäfer R; Kuban RJ; Ungethüm U; Györffy B; Neumann U; Simon E; Weichert W; Ebert MP; Röcken C
    J Pathol; 2010 Nov; 222(3):310-9. PubMed ID: 20726036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma.
    Vaksman O; Hetland TE; Trope' CG; Reich R; Davidson B
    Hum Pathol; 2012 Nov; 43(11):2062-9. PubMed ID: 22647351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer.
    Chan JK; Kiet TK; Blansit K; Ramasubbaiah R; Hilton JF; Kapp DS; Matei D
    Gynecol Oncol; 2014 Jun; 133(3):568-74. PubMed ID: 24680769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of Dicer expression is associated with breast cancer progression and recurrence.
    Khoshnaw SM; Rakha EA; Abdel-Fatah TM; Nolan CC; Hodi Z; Macmillan DR; Ellis IO; Green AR
    Breast Cancer Res Treat; 2012 Sep; 135(2):403-13. PubMed ID: 22821364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EIF2C, Dicer, and Drosha are up-regulated along tumor progression and associated with poor prognosis in bladder carcinoma.
    Zhang Z; Zhang G; Kong C; Bi J; Gong D; Yu X; Shi D; Zhan B; Ye P
    Tumour Biol; 2015 Jul; 36(7):5071-9. PubMed ID: 25656609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
    Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
    Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer.
    Ma Y; Zhang P; Wang F; Zhang H; Yang J; Peng J; Liu W; Qin H
    Gut; 2012 Oct; 61(10):1447-53. PubMed ID: 22052060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.